The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
Open accessAbstract
The anecdotal reports of promising results seen with immunotherapy and radiation in advanced malignancies have prompted several trials combining immunotherapy and radiation. However, the ideal timing of immunotherapy with radiation has not been clarified. Tumor bearing mice were treated with 20Gy radiation delivered only to the tumor combined with either anti-CTLA4 antibody or anti-OX40 agonist antibody. Immunotherapy was delivered at a single timepoint around radiation. Surprisingly, the optimal timing of these therapies varied. Anti-CTLA4 was most effective when given prior to radiation therapy, in part due to regulatory T cell depletion. Administration of anti-OX40 agonist antibody was optimal when delivered one day following radiation during the post-radiation window of increased antigen presentation. Combination treatment of anti-CTLA4, radiation, and anti-OX40 using the ideal timing in a transplanted spontaneous mammary tumor model demonstrated tumor cures. These data demonstrate that the combination of immunotherapy and radiation results in improved therapeutic efficacy, and that the ideal timing of administration with radiation is dependent on the mechanism of action of the immunotherapy utilized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.954 · Cited by 1,631
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · cited 1×
“Recent reports demonstrate that anti-CTLA4 antibodies cause Fc-dependent depletion of regulatory T cells in the tumor [19, 20] and it has been shown that depletion of regulatory T cells concurrent or following radiation therapy resulted in enhanced tumor control.”
BackgroundSharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., & Drake, C. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0196 · Cited by 658
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 496
Self-citationFilatenkov, A., Baker, J., Mueller, A. M. S., Kenkel, J., Ahn, G.-O., Dutt, S., Zhang, N., Kohrt, H., Jensen, K., Dejbakhsh-Jones, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2824 · Cited by 474
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yu, P., Fu, Y.-X., Weichselbaum, R. R., Rowley, D. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062056 · Cited by 359
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Westcott, P. M. K., Halliwill, K. D., To, M. D., Rashid, M., Rust, A. G., Keane, T. M., Delrosario, R., Jen, K.-Y., Gurley, K. E., Kemp, C. J., et al. (2015) · Nature · doi:10.1038/nature13898 · Cited by 330
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses
Seung, S. K., Curti, B. D., Crittenden, M., Walker, E., Coffey, T., Siebert, J. C., Miller, W., Payne, R., Glenn, L., Bageac, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003649 · Cited by 303
Self-citationTransient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130762 · Cited by 296
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., & Knox, S. J. (2012) · Translational Oncology · doi:10.1593/tlo.12280 · Cited by 247
Stein, W. D., Gulley, J. L., Schlom, J., Madan, R. A., Dahut, W., Figg, W. D., Ning, Y.-M., Arlen, P. M., Price, D., Bates, S. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1762 · Cited by 247
Belcaid, Z., Phallen, J. A., Zeng, J., See, A. P., Mathios, D., Gottschalk, C., Nicholas, S., Kellett, M., Ruzevick, J., Jackson, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101764 · Cited by 244
Establishment of mouse colonic carcinoma cell lines with different metastatic properties.
Brattain, M. G., Strobel‐Stevens, J. D., Fine, D., et al. (1980) · PubMed · Cited by 234
OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
Gough, M. J., Ruby, C. E., Redmond, W. L., Dhungel, B., Brown, A., & Weinberg, A. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6484 · Cited by 174
Self-citationRedmond, W. L., Linch, S. N., & Kasiewicz, M. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0031-t · Cited by 168
Liang, H., Deng, L., Chmura, S., Burnette, B., Liadis, N., Darga, T., Beckett, M. A., Lingen, M. W., Witt, M., Weichselbaum, R. R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202612 · Cited by 165
Gough, M. J., Crittenden, M. R., Sarff, M., Pang, P., Seung, S. K., Vetto, J. T., Hu, H.-M., Redmond, W. L., Holland, J., & Weinberg, A. D. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee7095 · Cited by 160
Self-citationHuang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Barker, C. A., Postow, M. A., Khan, S. A., Beal, K. P., Parhar, P. K., Yamada, Y. J., Lee, N. Y., & Wolchok, J. D. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0082 · Cited by 150
Expression of NF-κB p50 in Tumor Stroma Limits the Control of Tumors by Radiation Therapy
Crittenden, M. R., Cottam, B., Savage, T., Nguyen, C., Newell, P., & Gough, M. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039295 · Cited by 116
Self-citationInvariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade
Pilones, K. A., Kawashima, N., Yang, A. M., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1277 · Cited by 102
Evans, D. E., Prell, R. A., Thalhofer, C., Hurwitz, A. A., & Weinberg, A. D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6804 · Cited by 95
Yokouchi, H., Yamazaki, K., Chamoto, K., Kikuchi, E., Shinagawa, N., Oizumi, S., Hommura, F., Nishimura, T., & Nishimura, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00664.x · Cited by 90
TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models
Young, K. H., Newell, P., Cottam, B., Friedman, D. J., Savage, T., Baird, J. R., Akporiaye, E. T., Gough, M. J., & Crittenden, M. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0207 · Cited by 61
Self-citationCrittenden, M. R., Savage, T., Cottam, B., Bahjat, K. S., Redmond, W. L., Bambina, S., Kasiewicz, M. J., Newell, P., Jackson, A. M., & Gough, M. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069527 · Cited by 46
Self-citationImmune System Plays an Important Role in the Success and Failure of Conventional Cancer Therapy
Gough, M. J., & Crittenden, M. R. (2012) · Immunotherapy · doi:10.2217/imt.11.157 · Cited by 25
Self-citation
Cited by
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W., & Lin, S. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00185 · Cited by 374
Marciscano, A. E., Ghasemzadeh, A., Nirschl, T. R., Theodros, D., Kochel, C. M., Francica, B. J., Muroyama, Y., Anders, R. A., Sharabi, A. B., Velarde, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3427 · Cited by 335
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 321
Self-citation
Metadata
- Authors
- Young, K. H., Baird, J. R., Savage, T., Cottam, B., Friedman, D., Bambina, S., Messenheimer, D. J., Fox, B., Newell, P., Bahjat, K. S., Gough, M. J., & Crittenden, M. R.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-09
- Volume
- 11
- Issue
- 6
- Pages
- e0157164
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2411685931
- Cited by
- 325
- References
- 37
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.